Korean J Hematol 2009; 44(2):
Published online June 30, 2009
https://doi.org/10.5045/kjh.2009.44.2.92
© The Korean Society of Hematology
안미선 엄영우 박준성 최진혁 강석윤 이현우 양말숙 김효은 장인근 이종은 김영진 김효철 정성현
아주대학교 의과대학 종양혈액내과학교실,
라이프코드 부설 생의학 연구실
Background: On performing umbilical cord blood (UCB) transplantation, faster engraftment may lead better clinical outcome. Because transplanted viable cell count in UCB is related to the engraftment, accurate evaluation of viability of CD34+ cells in cryopreserved UCB has clinical implication. We examined the difference in viability of cells in cryopreserved UCB according to the duration of cryopreservation and different methods.
Methods: A total of 60 UCB samples which were cryopreserved for 1 to 4 years were used in this study. Viability of cryopreserved cells were examined with trypan blue exclusion assay, DNA contents analysis, caspase-3 activation test, intracellular esterase activity and Annexin-V/PI staining.
Results: After thawing the cryopreserved UCB, 89% of the total MNCs and 84% of CD34+ cells were viable as identified by trypan blue exclusion assay. In the CD34+ cell population, the cell death rate was found to be 47% by Annexin-V/PI staining and less than 5% by DNA contents analysis. However, cspase-3 activity failed to document apoptosis. The intracellular esterase activity test also showed a cell death rate of about 10∼20% at 2, 4, and 6 hours after thawing.
Conclusion: Viable cells in UCB should be measured by several compensatory techniques rather than a single method. Discordance among Annexin-V/PI staining versus trypan blue exclusion, DNA contents analysis, and the caspase-3 activation test or intracellular esterase activity should be clarified in order to apply these techniques for actual cord blood transplantation. (Korean J Hematol 2009;44:92-99.)
Keywords Umbilical cord blood, Apoptosis, Viability
Korean J Hematol 2009; 44(2): 92-99
Published online June 30, 2009 https://doi.org/10.5045/kjh.2009.44.2.92
Copyright © The Korean Society of Hematology.
안미선 엄영우 박준성 최진혁 강석윤 이현우 양말숙 김효은 장인근 이종은 김영진 김효철 정성현
아주대학교 의과대학 종양혈액내과학교실,
라이프코드 부설 생의학 연구실
Mi Sun Ahn, Young woo Eom, Joon Seong Park, Jin Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Mal Sook Yang, Hyo Eun Kim, In Keun Jang, Jong Eun Lee, Young Jin Kim, Hugh Chul Kim, Seong Hyun Jeong
Department of Hematology-Oncology, Ajou University School of Medicine
Biomedical Research Institute, LifeCord Inc., Suwon, Korea
Background: On performing umbilical cord blood (UCB) transplantation, faster engraftment may lead better clinical outcome. Because transplanted viable cell count in UCB is related to the engraftment, accurate evaluation of viability of CD34+ cells in cryopreserved UCB has clinical implication. We examined the difference in viability of cells in cryopreserved UCB according to the duration of cryopreservation and different methods.
Methods: A total of 60 UCB samples which were cryopreserved for 1 to 4 years were used in this study. Viability of cryopreserved cells were examined with trypan blue exclusion assay, DNA contents analysis, caspase-3 activation test, intracellular esterase activity and Annexin-V/PI staining.
Results: After thawing the cryopreserved UCB, 89% of the total MNCs and 84% of CD34+ cells were viable as identified by trypan blue exclusion assay. In the CD34+ cell population, the cell death rate was found to be 47% by Annexin-V/PI staining and less than 5% by DNA contents analysis. However, cspase-3 activity failed to document apoptosis. The intracellular esterase activity test also showed a cell death rate of about 10∼20% at 2, 4, and 6 hours after thawing.
Conclusion: Viable cells in UCB should be measured by several compensatory techniques rather than a single method. Discordance among Annexin-V/PI staining versus trypan blue exclusion, DNA contents analysis, and the caspase-3 activation test or intracellular esterase activity should be clarified in order to apply these techniques for actual cord blood transplantation. (Korean J Hematol 2009;44:92-99.)
Keywords: Umbilical cord blood, Apoptosis, Viability
Seong-Ho Kang, Ji Seon Choi
Blood Res 2023; 58(3): 133-137Taghi Khanzadeh, Majid Farshdousti Hagh, Mehdi Talebi, Bahman Yousefi, Ako Azimi, Abbas Ali Hossein pour feizi, and Behzad Baradaran
Blood Res 2018; 53(1): 53-60Masashi Ohe, Satoshi Hashino, and Atsuo Hattori
Korean J Hematol 2012; 47(4): 293-297